SF1126

SF1126 · Semafore Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SF1126, covering 2013-06-13 to 2018-06-11. Get the full timeline:

Most recent: Clinical Trial Update: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes [Phase 2]